Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (8): 1509-1512.doi: 10.3969/j.issn.1673-8225.2012.08.040

Previous Articles     Next Articles

Effects of chitosan-phosphatidylcholine complex on serum interleukin 1 beta and tumor necrosis factor alpha in mild cognitive impairment patients  

Wu Jing-lin1, Meng Qing-hui1, Hou Wen-xia1, Xie Hai2   

  1. 1College of Nursing, Weifang Medical University, Weifang  261053, Shandong Province, China; 2Department of Nuclear Medicine, Affiliated Hospital of Weifang Medical School, Weifang  261051, Shandong Province, China
  • Received:2011-08-15 Revised:2011-09-17 Online:2012-02-19 Published:2012-02-19
  • Contact: Meng Qing-hui, Doctor, Associate professor, College of Nursing, Weifang Medical University, Weifang 261053, Shandong Province, China hui_m12@163.com
  • About author:Wu Jing-lin★, Studying for master’s degree, College of Nursing, Weifang Medical University, Weifang 261053, Shandong Province, China wujinglin2009@ 163.com
  • Supported by:

     the Natural Science Foundation of Shandong Province, No. Y2008C125*; Science and Technology Foundation of Shandong Educational Department, No. J08LH67*

PDF

587

Abstract:

BACKGROUND: Chitosan phosphatidylcholine can improve the symptoms of Alzheimer's disease through the blood-brain barrier.
OBJECTIVE: To explore the influence of chitosan-phosphatidylcholine complex on serum interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) and mini-mental state examination (MMSE) in mild cognitive impairement (MCI) patients.
METHODS: According to diagnostic criteria of MCI, 36 patients with MCI selected from a part of homes and communities in Weifang City were randomly divided into experimental group (oral administration of chitosan phosphatidylcholine), black control group (without taking medication) and healthy control group with the age and education-matched. Serum IL-1β and TNF-α concentration among three groups were detected by using radioimmunoassay.
RESULTS AND CONCLUSION: Compared with the black control group, serum IL-1β and TNF-α levels were significantly decreased in the experimental group post-treatment, and serum IL-1β and TNF-α levels in the experimental group post-treatment were significantly lower than that in the experimental group pre-treatment (P < 0.05). MMSE score was significantly improved in the experimental group post-treatment compared with experimental group pre-treatment (P < 0.05). It is indicated that chitosan phosphatidylcholine can improve cognitive function of MCI patients, lower serum IL-1β and TNFα levels, reduce inflammatory reaction and delay the MCI progression.

CLC Number: